Compass Therapeutics (CMPX) Cash from Financing Activities (2018 - 2026)

Compass Therapeutics has reported Cash from Financing Activities for 9 years, with the latest figure at $3.4 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 512.88% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $133.8 million (up 14802.09% YoY) and the FY2025 annual result came in at $129.6 million, up 647.54% from the prior year.
• Cash from Financing Activities improved to $3.4 million in Q1 2026 per CMPX's latest filing, from $1.1 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $129.4 million in Q3 2025 and troughed at -$815000.0 in Q1 2025.
• A 5-year average of $16.4 million and a median of $31000.0 in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities slumped 109.52% in 2024, then soared 6468150.0% in 2025.
• Over 5 years, Cash from Financing Activities stood at $75.8 million in 2022, then sank by 100.21% to -$158000.0 in 2023, then jumped by 40.51% to -$94000.0 in 2024, then surged by 1230.85% to $1.1 million in 2025, then jumped by 216.56% to $3.4 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $3.4 million, $1.1 million, and $129.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.